Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Conditions
Keywords
Relapsed, Refractory, B-ALL
Brief summary
This is a single arm, open-label, single center study to determine the safety and efficacy of CD19-CD22 CAR-T cells in patients with CD19+CD22+ Leukemia.
Detailed description
This is a single arm, open-label, single center study to determine the safety and efficacy of CD19-CD22 CAR-T cells in patients with relapsed or refractory B-ALL. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Follow-up, and Survival Follow-up. The total duration of the study is 2 years from CD19-CD22 CAR-T cell infusion.
Interventions
BIOLOGICALCD19-CD22 CAR-T cells
0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.
Sponsors
Juventas Cell Therapy Ltd.
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Informed consent is signed by a subject or his lineal relation. 2. Age 3 and older. 3. Documentation of cluster of differentiation 19 (CD19) and or cluster of differentiation 19 (CD22) expression on leukemic blasts in the BM, peripheral blood within 3 months of screening.; 4. Relapsed or refractory B-cell ALL * Relapse within 12 months of first remission * Without remission after 2 cycles of induction chemotherapy regimen. * Without remission or relapse after salvage treatments. * Any BM relapse after autologous stem cell transplantation (ASCT). 5. Without remission or relapse after any prior CD19 targeted therapy; 6. Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they are intolerant to or have failed 2 lines of tyrosine kinase inhibitor therapy (TKI); no TKI salvage treatments if the patient has a BCR-ABL1 kinase domain gatekeeper mutation Thr315Ile (T315I) mutation. 7. Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening； 8. Eastern cooperative oncology group (ECOG) performance status of 0 to 2. 9. Adequate organ function defined as: * Aspartate aminotransferase (AST) ≤3 upper limit of normal (ULN); * Serum alanine aminotransferase (ALT) ≤3 ULN; * Total bilirubin ≤ 2 ULN, except in individuals with Gilbert's syndrome; * Note: Patients with Gilbert's syndrome that bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN will be eligible. * A serum creatinine≤ 1.5 ULN or Creatine removal rate ≥ 60mL/min（Cockcroft and Gault） * Must have a minimum level of pulmonary reserve as ≤ Grade 1 dyspnea and oxygen saturation \> 91% on room air. * Absolute lymphocyte count ≥0.3 x 10⁹/L. 10. Women of child-bearing potential and all male participants must use highly effective methods of contraception for a period of 1 year after the CD19-CD22 CAR-T cells infusion.
Exclusion criteria
1. Active central nervous system leukemia 2. Patients with evidence of currently uncontrollable serious active infections (e.g., sepsis, bacteremia, fungemia, viremia, etc.). 3. Patients who are positive for any of HIV antibody, TP antibody, hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) antibody. 4. Major surgery within ≤ 4 weeks before enrollment. 5. Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent. 6. Impaired cardiac function: * Left Ventricular Ejection Fraction (LVEF) ≤45%; * III/IV congestive heart failure (NYHA); * Severe arrhythmia (except for Atrial fibrillation, Paroxysmal supraventricular tachycardia); * Corrected QT interval (QTc) ≥450ms (male) or QTc≥470ms (female)（QTc using Bazett's formula (QTcB)=QT/RR\^0.5）; * Myocardial infarction or Coronary Artery Bypass Graft Surgery, heart stent surgery. * Other heart diseases that have been judged by the investigator to be unsuitable for receiving cell therapy. 7. Patients with a history of epilepsy or other active central nervous system diseases. 8. Life expectancy \< 12 weeks. 9. Allergy to macromolecule biopharmaceuticals such as antibodies or cytokines. 10. Subjects who are receiving systemic steroid treatment and who have been determined by the researchers to require long-term treatment with systemic steroids during treatment, and subjects treated with systemic steroids must be excluded \< 72 hours prior to CNCT19 infusion (except inhalation or local use). 11. Patients with other conditions making the patients unsuitable for receiving cell therapy as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | 24 months |
| Overall remission rate (ORR) | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of patients who achieve CR or CRi with minimal residual disease (MRD) negative bone marrow | 6 months |
| Relapse-free survival (RFS) | 24 months |
| Response at Day 28 days | 1 month |
| Overall survival (OS) | 24 months |
| Duration of remission (DOR) | 24 months |
| Percentage of patients who achieve complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at month 6 without SCT between CD19-CD22 CAR-T cells infusion and Month 6 response assessment. | 6 months |
Countries
China
Outcome results
None listed